NCT04739813 2026-02-24
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
National Institutes of Health Clinical Center (CC)
CellCentric Ltd.
M.D. Anderson Cancer Center
Weill Medical College of Cornell University
AbbVie
Melbourne Health